Navigation Links
Safer, cheaper building blocks for future anti-HIV and cancer drugs

A team of researchers from KU Leuven, in Belgium, has developed an economical, reliable and heavy metal-free chemical reaction that yields fully functional 1,2,3-triazoles. Triazoles are chemical compounds that can be used as building blocks for more complex chemical compounds, including pharmaceutical drugs.

Leveraging the compound's surprisingly stable structure, drug developers have successfully used 1,2,3-triazoles as building blocks in various anti-HIV, anti-cancer and anti-bacterial drugs. But efforts to synthesize the compound have been hampered by one serious hurdle: they depend on harmful heavy metals to work, and this severely limits their biological applications.

In new experiments reported in the journal Angewandte Chemie, Dr. Joice Thomas, Prof. Dr. Wim Dehaen and their team at KU Leuven's Molecular Design and Synthesis lab confirm for the first time that 1,2,3-triazoles can be synthesized through a metal-free, three-component reaction using readily available ingredients.

"We were able to develop a reaction that provided a good yield, high regioselectivity and easy access to diversely functionalized 1,2,3-triazoles," says corresponding author Prof. Dr. Wim Dehaen. "In other words, the reaction produces plenty of the compounds we're looking for, does so reliably without unwanted or unexpected outcomes, and does this in a way that makes it easy for us to isolate the compound. This makes our method highly desirable."

"Moving forward, we will focus on expanding the chemistry developed here to other new reactions while also exploring their possible applications in pharmaceutical as well as supra-molecular sciences," says lead author Dr. Joice Thomas.


Contact: Wim Dehaen
KU Leuven

Page: 1

Related biology news :

1. New class of nanoparticle brings cheaper, lighter solar cells outdoors
2. Shifting evolution into reverse promises cheaper, greener way to make new drugs
3. Now it will become cheaper to make second-generation biofuel for our cars
4. A quicker, cheaper way to detect staph in the body
5. Iron-based process promises greener, cheaper and safer drug and perfume production
6. New method to diagnose sepsis is faster, cheaper
7. Novel LEDs pave the way to cheaper displays
8. Team uses forest waste to develop cheaper, greener supercapacitors
9. A route for steeper, cheaper, and deeper roots
10. Breakthrough could lead to cheaper, more sustainable chemical production
11. Waste cooking oil makes bioplastics cheaper
Post Your Comments:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology: